|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2004-6-1
|
|
pubmed:abstractText |
Many cases of hypereosinophilia, formerly classified as hypereosinophilic syndrome, can now be characterized as chronic eosinophilic leukemia (CEL) based on the demonstration of characteristic genetic markers indicating clonality of hematopoiesis. Here we report on a 33-year-old male patient with central nervous system manifestations of CEL and an excellent response to low-dose imatinib (Glivec). Molecular analysis demonstrated a constitutive activation of the platelet-derived growth factor receptor-alpha (PDGFR-A) as the mechanism of responsiveness to imatinib.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Azathioprine,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/FIP1L1-PDGFRA fusion protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Oncogene Proteins, Fusion,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisone,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Platelet-Derived Growth...,
http://linkedlifedata.com/resource/pubmed/chemical/imatinib,
http://linkedlifedata.com/resource/pubmed/chemical/mRNA Cleavage and Polyadenylation...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0939-5555
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
83
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
477-80
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:14986065-Adult,
pubmed-meshheading:14986065-Antineoplastic Agents,
pubmed-meshheading:14986065-Arm,
pubmed-meshheading:14986065-Azathioprine,
pubmed-meshheading:14986065-Brain,
pubmed-meshheading:14986065-Cerebellar Ataxia,
pubmed-meshheading:14986065-Cerebellar Cortex,
pubmed-meshheading:14986065-Enzyme Inhibitors,
pubmed-meshheading:14986065-Headache,
pubmed-meshheading:14986065-Humans,
pubmed-meshheading:14986065-Hypereosinophilic Syndrome,
pubmed-meshheading:14986065-Immunosuppressive Agents,
pubmed-meshheading:14986065-Leukemic Infiltration,
pubmed-meshheading:14986065-Magnetic Resonance Imaging,
pubmed-meshheading:14986065-Male,
pubmed-meshheading:14986065-Memory Disorders,
pubmed-meshheading:14986065-Oncogene Proteins, Fusion,
pubmed-meshheading:14986065-Paresis,
pubmed-meshheading:14986065-Parietal Lobe,
pubmed-meshheading:14986065-Piperazines,
pubmed-meshheading:14986065-Polyarteritis Nodosa,
pubmed-meshheading:14986065-Prednisone,
pubmed-meshheading:14986065-Pyrimidines,
pubmed-meshheading:14986065-Receptor, Platelet-Derived Growth Factor alpha,
pubmed-meshheading:14986065-Remission Induction,
pubmed-meshheading:14986065-Vertigo,
pubmed-meshheading:14986065-mRNA Cleavage and Polyadenylation Factors
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib.
|
|
pubmed:affiliation |
Department of Hematology/Oncology, Dr.-Horst-Schmidt-Kliniken GmbH, Wiesbaden, Germany. norbert.frickhofen@hsk-wiesbaden.de
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
